Biology and bioinformatics of myeloma cell

Laboratory Hematology

Volumn 18, Issue 4, 2012, Pages 30-41

  Abroun, Saeid ^a   Saki, Najmaldin ^b   Fakher, Rahim ^b   Asghari, Farahnaz ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Bioinformatics; Chemokines; Multiple myeloma; Signaling pathways

Indexed keywords

CD19 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD33 ANTIGEN; CD38 ANTIGEN; CD44V ANTIGEN; CD45 ANTIGEN; CD81 ANTIGEN; CD86 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; INTERLEUKIN 6 RECEPTOR ALPHA; NOTCH RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SYNDECAN 1; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR RUNX2; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; B LYMPHOCYTE; BIOINFORMATICS; BONE LESION; CANCER STAGING; CHROMOSOME ABERRATION; COMPUTER MODEL; CYTOLOGY; DRUG DESIGN; GENE TRANSLOCATION; GENETIC ANALYSIS; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; WNT SIGNALING PATHWAY;

ANTIGENS, CD; BIOLOGICAL MARKERS; BONE MARROW; COMPUTATIONAL BIOLOGY; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELLS; HUMANS; MODELS, MOLECULAR; MULTIPLE MYELOMA; NEOPLASM STAGING; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 84875496905     PISSN: 10802924     EISSN: None     Source Type: Journal    
DOI: 10.1532/LH96.11003     Document Type: Article

References (101)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324-339.
2. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
3. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3-9.
4. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
5. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
6. Czaplinski A, Steck AJ. Immune mediated neuropathies-an update on therapeutic strategies. J Neurol. 2004;251:127-137.
7. Blade J. Clinical practice. Monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;355:2765-2770.
8. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962-2972.
9. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
10. Magrangeas F, Nasser V, Avet-Loiseau H, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood. 2003;101:4998-5006.
11. Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol. 1998;152:1655-1665.
12. Mårtensson IL, Almqvist N, Grimsholm O, Bernardi AI. The pre-B cell receptor checkpoint. FEBS Lett. 2010;584:2572-2579.
13. Vale AM, Schroeder HW Jr. Clinical consequences of defects in B-cell development. J Allergy Clin Immunol. 2010;125:778-787.
14. Fairfax KA, Kallies A, Nutt SL, Tarlinton DM. Plasma cell development: From B-cell subsets to long-term survival niches. Semin Immunol. 2008;20:49-58.
15. Sirohi B, Powles R. Multiple myeloma. Lancet. 2004;363:875-887.
16. Rahim F. In silico comparison of simple sequence repeats in high nucleotides-rich genomes of microorganism. Pak J Biol Sci. 2008;11:2372-2381.
17. Chen L, Li J, Xu W, et al. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization. Exp Oncol. 2007;29:116-120.
18. Chiecchio L, Dagrada GP, Ibrahim AH, et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica. 2009;94:1708-1713.
19. Liebisch P, Döhner H. Cytogenetics and molecular cytogenetics in multiple myeloma. Eur J Cancer. 2006;42:1520-1529.
20. Pratt G. Molecular aspects of multiple myeloma. Mol Pathol. 2002;55:273-283.
21. Bataille R, Jégo G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica. 2006;91:1234-1240.
22. Brito JL, Walker B, Jenner M, et al. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica. 2009;94:78-86.
23. Cassinelli G, Ronchetti D, Laccabue D, et al. Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting. Biochem Pharmacol. 2009;78:1139-1147.
24. Bisping G, Wenning D, Kropff M, et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. Clin Cancer Res. 2009;15:520-531.
25. Reece DE. Management of multiple myeloma: The changing landscape. Blood Rev. 2007;21:301-314.
26. Cao S, Liu J, Song L, Ma X. The protooncogene c-Maf is an essential transcription factor for IL-10 gene expression in macrophages. J Immunol. 2005;174:3484-3492.
27. Athanasiou E, Kaloutsi V, Kotoula V, et al. Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens. Am J Clin Pathol. 2001;116:535-542.
28. Ngo BT, Felthaus J, Hein M, et al. Monitoring bortezomib therapy in multiple myeloma: Screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome. Leuk Lymphoma. 2010;51:1632-1642.
29. Saki N, Abroun S, Farshdousti Hagh M, Asgharei F. Neoplastic bone marrow niche: Hematopoietic and mesenchymal stem cells. Cell J (Yakhteh). 2011;13:131-6.
30. Basak GW, Srivastava AS, Malhotra R, Carrier E. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol. 2009;10:345-346.
31. Dib IE, Gressier M, Salle V, Mentaverri R, Brazier M, Kamel S. Multiple myeloma cells directly stimulate bone resorption in vitro by down-regulating mature osteoclast apoptosis. Leuk Res. 2008;32:1279-1287.
32. Sezer O. Myeloma bone disease: Recent advances in biology, diagnosis, and treatment. Oncologist. 2009;14:276-283.
33. Roodman GD. Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab. 2010;28:244-250.
34. Abroun S, Sadeghi B, Poopak B, Hajfathali A, Saki N, Vaghef N. The role of myeloma cells to osteoclast activation. Cell J (Yakhteh). 2010;12:357-62.
35. Jakob C, Goerke A, Terpos E, et al. Serum levels of total-RANKL in multiple myeloma. Clin Lymphoma Myeloma. 2009;9:430-435.
36. San Miguel JF, Gutiérrez NC, Mateo G, Orfao A. Conventional diagnostics in multiple myeloma. Eur J Cancer. 2006;42:1510-1519.
37. Terpos E, Dimopoulos MA. Myeloma bone disease: Pathophysiology and management. Ann Oncol. 2005;16:1223-1231.
38. Corre J, Mahtouk K, Attal M, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007;21:1079-1088.
39. Silvestris F, Ciavarella S, De Matteo M, Tucci M, Dammacco F. Bone-resorbing cells in multiple myeloma: Osteoclasts, myeloma cell polykaryons, or both? Oncologist. 2009;14:264-275.
40. Edwards CM, Zhuang J, Mundy GR. The pathogenesis of the bone disease of multiple myeloma. Bone. 2008;42:1007-1013.
41. Saki N, Abroun S, Soleimani M, Kaviani S, Sadeghi B, Vaghef N. The role of myeloma cells in the in vitro differentiation of cord blood hematopoietic stem cell to osteoclast. Modares J Med Sci (Pathobiol). 2010;13:53-61.
42. Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol. 2006;34:1289-1295.
43. Abroun S. Chemokines in homeostasis and cancers. Cell J (Yakhteh). 2008;10:155-66.
44. Abroun S, Ishikawa H, Tsuyama N, et al. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected]. Blood. 2004;103:2291-2298.
45. Heider U, Fleissner C, Zavrski I, et al. Bone markers in multiple myeloma. Eur J Cancer. 2006;42:1544-1553.
46. Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci. 2006;1092:385-396.
47. Kawano MM, Ishikawa H, Tsuyama N, et al. Growth mechanism of human myeloma cells by interleukin-6. Int J Hematol. 2002;76 Suppl 1:329-333.
48. Sprynski AC, Hose D, Caillot L, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 2009;113:4614-4626.
49. Menu E, van Valckenborgh E, van Camp B, Vanderkerken K. The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Arch Physiol Biochem. 2009;115:49-57.
50. Nishimoto N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther. 2010;87:483-487.
51. Gavriatopoulou M, Dimopoulos MA, Christoulas D, et al. Dickkopf-1: A suitable target for the management of myeloma bone disease. Expert Opin Ther Targets. 2009;13:839-848.
52. Qiang YW, Shaughnessy JD Jr, Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood. 2008;112:374-382.
53. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia. 2006;20:193-199.
54. Mahmoud MS, Huang N, Nobuyoshi M, Lisukov IA, Tanaka H, Kawano MM. Altered expression of Pax-5 gene in human myeloma cells. Blood. 1996;87:4311-4315.
55. Ishikawa H, Tsuyama N, Mahmoud MS, et al. CD19 expression and growth inhibition of tumours in human multiple myeloma. Leuk Lymphoma. 2002;43:613-616.
56. Shamsasenjan K, Otsuyama K, Abroun S, et al. IL-6-induced activation of MYC is responsible for the down-regulation of CD33 expression in CD33+ myeloma cells. Int J Hematol. 2009;89:310-318.
57. Haylock DN, Nilsson SK. Osteopontin: A bridge between bone and blood. Br J Haematol. 2006;134:467-474.
58. Giuliani N, Colla S, Morandi F, Rizzoli V. Angiopoietin-1 and myeloma-induced angiogenesis. Leuk Lymphoma. 2005;46:29-33.
59. Ishikawa H, Mahmoud MS, Fujii R, Abroun S, Kawano MM. Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma. Leuk Lymphoma. 2000;39:51-55.
60. Ishikawa H, Tsuyama N, Abroun S, et al. Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation. Leuk Lymphoma. 2003;44:1477-1481.
61. Van Riet I, De Waele M, Remels L, Lacor P, Schots R, Van Camp B. Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells. Br J Haematol. 1991;79:421-427.
62. Katz BZ. Adhesion molecules-The lifelines of multiple myeloma cells. Semin Cancer Biol. 2001;20:186-195.
63. Gazitt Y, Akay C. Mobilization of myeloma cells involves SDF-1/CXCR4 signaling and downregulation of VLA-4. Stem Cells. 2004;22:65-73.
64. Jakob C, Sterz J, Zavrski I, et al. Angiogenesis in multiple myeloma. Eur J Cancer. 2006;42:1581-1590.
65. Chen L, Sanderson RD. Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One. 2009;4:e4947.
66. Al-Quran SZ, Yang L, Magill JM, Braylan RC, Douglas-Nikitin VK. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: The added value of CD138 immunohistochemistry. Hum Pathol. 2007;38:1779-1787.
67. Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica. 2005;90:706-707.
68. Bommert K, Bargou RC, Stühmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer. 2006;42:1574-1580.
69. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116:1202-1209.
70. Kochegarov A. Small molecules for stem cells. Expert Opin Ther Pat. 2009;19:275-281.
71. Peterlik M, Grant WB, Cross HS. Calcium, vitamin D and cancer. Anticancer Res. 2009;29:3687-3698.
72. Diamond T, Golombick T, Manoharan A. Vitamin D status may effect the skeletal complications of multiple myeloma. Am J Hematol. 2010;85:302-303.
73. Pearse RN. Wnt antagonism in multiple myeloma: A potential cause of uncoupled bone remodeling. Clin Cancer Res. 2006;12(20 Pt 2):6274s-6278s.
74. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008;4:68-75.
75. Desplanques G, Giuliani N, Delsignore R, Rizzoli V, Bataille R, Barillé-Nion S. Impact of XIAP protein levels on the survival of myeloma cells. Haematologica. 2009;94:87-93.
76. Shain KH, Yarde DN, Meads MB, et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: Implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 2009;69:1009-1015.
77. Giuliani N, Mangoni M, Rizzoli V. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: Identification of potential therapeutic targets. Exp Hematol. 2009;37:879-886.
78. Rubin MA, Chinnaiyan AM. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. Lab Invest. 2006;86:1099-1102.
79. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6:1-6.
80. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648.
81. Fuellen G. Evolution of gene regulation-on the road towards computational inferences. Brief Bioinform. 2001;12:122-131.
82. Flanagan SE, Patch AM, Ellard S. Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. Genet Test Mol Biomarkers. 2010;14:533-537.
83. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: Regional visualization of genome-wide association scan results. Bioinformatics. 2010;26:2336-2337.
84. Ettinger NA, Wilson ME. Macrophage and T-cell gene expression in a model of early infection with the protozoan Leishmania chagasi. PLoS Negl Trop Dis. 2008;2:e252.
85. Claudio JO, Masih-Khan E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma. Blood. 2002;100:2175-2186.
86. Zhou FL, Zhang WG, Chen G, et al. Immunological screening for multiple myeloma-associated antigens and their bioinformatics analysis [in Chinese]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006;14:252-257.
87. Biasiolo M, Forcato M, Possamai L, et al. Critical analysis of transcriptional and post-transcriptional regulatory networks in multiple myeloma. Pac Symp Biocomput. 2010:397-408.
88. del Val C, Mehrle A, Falkenhahn M, et al. High-throughput protein analysis integrating bioinformatics and experimental assays. Nucleic Acids Res. 2004;32:742-748.
89. Desany B, Zhang Z. Bioinformatics and cancer target discovery. Drug Discov Today. 2004;9:795-802.
90. Nagase T, Miyajima N, Tanaka A, et al. Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1 (supplement). DNA Res. 1995;2:51-59.
91. Zhou FL, Zhang WG, Chen G, et al. Serological identification and bioinformatics analysis of immunogenic antigens in multiple myeloma. Cancer Immunol Immunother. 2006;55:910-917.
92. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: A novel approach for cancer therapy. Annu Rev Pharmacol Toxicol. 2009;49:223-241.
93. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005;102:8567-8572.
94. Phillip CJ, Stellrecht CM, Nimmanapalli R, Gandhi V. Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol. 2009;63:587-597.
95. Kanagarajadurai K, Sowdhamini R. Sequence and structural analyses of interleukin-8-like chemokine superfamily. In Silico Biol. 2008;8:307-330.
96. Wong ES, Young LJ, Papenfuss AT, Belov K. In silico identification of opossum cytokine genes suggests the complexity of the marsupial immune system rivals that of eutherian mammals. Immunome Res. 2006;2:4.
97. Han W, Ding P, Xu M, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics. 2003;81:609-617.
98. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781-810.
99. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: Diseases and therapies. Nat Rev Genet. 2004;5:691-701.
100. Martin TJ. Paracrine regulation of osteoclast formation and activity: Milestones in discovery. J Musculoskelet Neuronal Interact. 2004;4:243-253.
101. Roccaro AM, Sacco A, Thompson B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009;113:6669-6680.